Cyclin A is a cell cycle regulatory protein that functions in mitotic and S phase control in mammalian cells. However, in contrast to other G 1 phase regulatory proteins, such as cyclin D, retinoblastoma protein and p16 INK4A , cyclin A seems not to be commonly involved in tumorigenesis. Recently, a second human cyclin A -cyclin A1 -has been identified. In contrast to cyclin A which is expressed throughout embryonic development and in adult tissue, the expression of cyclin A1 has been reported to be restricted to embryonic and germ line cells. We have confirmed the absence of cyclin A1 mRNA from normal peripheral blood leukocytes of seven healthy donors by single step reverse transcriptase-polymerase chain reaction (RT-PCR). Furthermore, we have examined the expression of cyclin A1 mRNA in 173 peripheral blood samples of 162 patients with various hematological malignancies. Cyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses. In addition, cyclin A1 mRNA was found in one of six leukapheresis products, harvested from individuals without hematological disorders. Taken together, cyclin A1 is expressed in the majority of myeloid and undifferentiated hematological malignancies as well as in normal hematopoietic progenitor cells. We conclude that cyclin A1, a protein potentially involved in G 1 /S phase progression of immature cells, might be necessary for proliferation of early hematopoietic progenitor cells and their leukemic counterparts being blocked at that stage of differentiation.
Introduction
Progression through the cell cycle is controlled by the sequential activation of a set of cyclin-dependent kinases (CDK). 1 The activities of the CDK are regulated by association with positive regulators -cyclins -as well as negative regulators referred to as CDK inhibitors. Cyclin gene expression is tightly regulated at the transcriptional level in a phase-specific manner. Expression of cyclin D1 is induced by serum growth factors 2 and is required for progression through early G 1 phase. 3 Cyclin E is synthesized in late G 1 phase and activates CDK2 by complex formation. 4 Cyclin E-CDK2 activity is regulated by the adhesion status of the cell 5, 6 and is rate-limiting for the transition through late G 1 . 7 Cyclin A gene transcription, which is cell cycle-and adhesion-dependent, 8, 9 starts at the G 1 /S boundary and is required for S phase entry, DNA replication and passage through G 2 . 10, 11 Phosphorylation and concomitant inactivation of the retinoblastoma protein (Rb) is induced Correspondence: A Krämer; Fax: 49 621 383 4201 Received 14 January 1998; accepted 9 March 1998 by complexes of CDK4/6 and cyclin D as well as CDK2 and cyclin E. 12 As a result, transcription factors E2F and CBP/cycA are released from Rb binding, and transcription of multiple genes that regulate cell proliferation is induced. 5, 8, 9, 13 Both CBP/cycA as well as E2F have been reported to transactivate cyclin A transcription 8, 9, 14 and CDK2-cyclin A activity is necessary for the transition from late G 1 to S phase. 10, 11 At this point the cell enters an irreversible state of the cell cycle. The kinase activity of the CDK4/6-cyclin D complex is inhibited by p16 INK4A and p15 INK4B , two members of a recently cloned family of CDK inhibitors. 15, 16 Deregulation of the cell cycle machinery, especially G 1 /S phase deregulation, is known to contribute to the development of solid tumors as well as hematological malignancies. While cyclins have been implicated as oncogenes when their expression is deregulated, [17] [18] [19] some CDK inhibitors are known to act as tumor suppressors in a wide range of malignancies. 16, 18, 20 Especially for lymphoid neoplasias several alterations of G 1 /S phase-regulating genes have been reported. Overexpression of cyclin D1 which acts as a positive regulator of G 1 phase progression by rearrangement of the bcl-1/PRAD1 locus on chromosome 11q13 with the immunoglobulin heavy chain gene on chromosome 14q23, 19 is the hallmark of mantle cell lymphoma 21 and has also been described in multiple myeloma 22 and atypical chronic lymphocytic leukemia. 23 In addition, homozygous deletions of the p16 INK4A and p16 INK4B CDK-inhibitor genes and loss of Rb expression are among the most frequently observed abnormalities in lymphoid tumors. [24] [25] [26] [27] [28] [29] [30] [31] The human cyclin A gene was originally identified as the site of hepatitis B virus integration in a hepatocellular carcinoma, and this integration and subsequent cyclin A overexpression may contribute to tumorigenesis. 32 In fibroblasts overexpression of cyclin A appears to advance S phase entry and confers anchorage-independent growth. 33, 34 In hematological malignancies, cyclin A expression correlates with the percentage of cells in S plus G 2 -M phase and thus with the proliferation rate of these disorders. 35 However, except for the single case of hepatocellular carcinoma mentioned above, cyclin A seems, per se, not to be implicated in tumorigenesis. 36 Instead, its expression in tumors seems to be a consequence of alterations earlier in G 1 phase.
Recently, a second human cyclin A -cyclin A1 -has been identified. 37 Cyclin A1 has 48% amino acid sequence identity with human cyclin A and 84% identity to the previously cloned murine cyclin A1. In mice and Xenopus, the expression of cyclin A1 is limited to embryonic and germ line tissue. 38, 39 In analogy, the expression of human cyclin A1 has been reported to be restricted to testis and, to a lesser extent, the brain. 37 In contrast, cyclin A is expressed throughout embryonic development and in adult tissues in Xenopus, mouse and man. The only available information on cyclin A1 expression in neoplasias has been provided by in vitro studies of tumor cell lines. 37 The aim of the present report was therefore to test for expression of cyclin A1 in tumor cells obtained 894 from patients with various hematological malignancies as well as in normal hematopoietic progenitor cells in leukapheresis products (LP) from individuals without hematological malignancies. Since cyclin A1 expression is known to be restricted to immature cells and expression of cyclin A1 mRNA has been demonstrated in acute leukemia cell lines, 37 we speculated that cyclin A1 might be expressed in early hematopoietic progenitor cells as well as in hematological malignancies derived thereof.
Materials and methods

Samples
One hundred and eighty peripheral blood samples were obtained from 162 patients with various hematological malignancies and from seven healthy individuals. Eleven patients had acute myeloid leukemia (AML), three patients had acute biphenotypic leukemia (BPL) according to the EGIL score system, 40 eight patients had myelodysplastic syndromes (MDS), 113 patients had chronic myelogenous leukemia (CML), 18 patients had chronic lymphocytic leukemia (CLL), nine patients had essential thrombocythemia (ET), and 10 patients had acute lymphoblastic leukemia (ALL). Of the 11 patients with AML, three had AML/FAB-M1, three had AML/FAB-M2, and one had AML/FAB-M5. For the remaining four patients with AML, no FAB classification was available. Six patients had primary AML, two and three patients had AML secondary to MDS and myeloproliferative disease, respectively. Of the eight patients with MDS, two had MDS/FAB-RAEB, one had MDS/FAB-RAEB-T, and four had MDS/FAB-CMML. For the remaining MDS patient no FAB classification was available. From the 113 patients with CML, 69 peripheral blood samples were obtained at diagnosis, 29 in chronic phase with hydroxyurea-and/or interferon ␣-therapy, and 15 in blastic transformation. Four CML blast crises had lymphoblastic, four myeloblastic, one monoblastic, and one megakaryoblastic differentiation. For five patients with CML in blastic transformation, no lineage determination was available. Of the 10 patients with ALL, nine had common-ALL and one had T-ALL. From seven ALL patients cDNA was obtained at diagnosis. In the remaining three cases, the cDNAs stemmed from the first, second and third relapse, respectively. Furthermore, six LP were examined. One LP was harvested from a patient with stage I breast cancer. Peripheral blood stem cells were collected during recombinant human granulocyte colony-stimulating factor (rhG-CSF; 300 g/day, s.c.)-enhanced bone marrow recovery following a mobilization chemotherapy with ifosfamide (10 g/m 2 ) and epirubicin (100 mg/m 2 ). Five LP were collected from four healthy individuals during stimulation of hematopoiesis with rhG-CSF (11-13 g/kg body weight/day). Informed consent was obtained from all subjects in the study.
Cell lines
cDNA from cell lines K562, BV173, KCL22, KYO1, KU812, LAMA, SD-1 and HL60 [41] [42] [43] was kindly provided by Dr Junia V Melo (Imperial College School of Medicine, London, UK). KG-1a 44 cells were donated by Dr Stefan Frü hauf (Medizinische Klinik und Poliklinik V, University of Heidelberg, Germany). Cell lines K562 and NB4 45 were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany).
Processing of samples
Leukocytes from patients and normal individuals were isolated from 10-20 ml of peripheral blood by red-cell lysis of centrifuged buffy-coat preparations. For analysis of LP, 1 ml aliquots were used. Total RNA was extracted from the leukocyte preparations, 10 8 cells per cell line, and LP aliquots by ultracentrifugation (CsCl gradient) or using the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The RNA was reverse transcribed into cDNA with MMLV reverse transcriptase using random hexamers as primers. 46 RT-PCR analysis PCR amplification of cyclin A1 cDNA was done with primers CycA1
+ (5′-GCCTGGCAAACTATACTGTG-3′) and CycA1 − (5′-CTCCATGAGGGACACACACA-3′). The primers were designed to span a region of 197 base pairs (bp) of the cyclin A1 cDNA, 37 as published. The PCR was set up in 22 l volume containing 10 mM Tris, pH 8.3, 50 mM KCl, 2.0 mM MgCl 2 , 200 M each dATP, dCTP, dGTP and dTTP, 0.5 mM each 5′ and 3′ primer, 0.5 U Taq polymerase and 2 l cDNA. All PCR experiments included a negative control reaction without DNA template. Rigorous precautions were taken to avoid the possibility of false positive results, as described elsewhere. 47 Thermocycling conditions were: one cycle of denaturing at 100°C for 10 s and 96°C for 1 min, annealing at 60°C for 3 min, and extension at 72°C for 2 min; 32 cycles of denaturing at 100°C for 10 s and 97°C for 20 s, annealing at 60°C for 50 s, extension at 78°C for 10 s, and 73°C for 50 s, followed by a final extension at 73°C for 10 min. Ten microliters of reaction products were electrophoresed through ethidium bromide-stained 1.8% agarose gel, visualized and photographed under UV light. cDNA quality was ensured by a single step multiplex PCR for BCR-ABL and BCR transcripts 46 and/or single step PCR for ABL transcripts. 48 
Southern blot analysis
Ten microliters of PCR product were electrophoresed through a 1.8% agarose gel, transferred by Southern blotting to a nylon membrane, pre-hybridized at 43°C for 2 h and hybridized at 43°C overnight to a 25-mer synthetic oligonucleotide cyclin A1 probe (5′-TAATTGCTTGCTGAGGTCGATGGGG-3′). The membrane was washed in 2 × SSC plus 0.1% SDS at room temperature and exposed to radiographic film at −70°C for 6 h.
cDNA sequencing Cyclin A1 RT-PCR products were electrophoresed through a 1.8% agarose gel, the 197 bp band was extracted by electroelution and sequenced using the Pharmacia T7 sequencing kit (Pharmacia, Erlangen, Germany) according to the manufacturer's recommendations. The sequencing products were run on a 6.0% polyacrylamide gel and exposed for 24 h.
Results
Cyclin A1 expression in hematological malignancies
A total of 173 peripheral blood samples from 162 patients with various hematological malignancies were analyzed by single step RT-PCR. Cyclin A1 mRNA could be detected in peripheral blood samples from 11 of 11 (100%) patients with AML, three of three (100%) patients with BPL, eight of eight (100%) patients with MDS, 59 of 69 (86%) patients with BCR-ABL positive CML at diagnosis, 12 of 29 (41%) patients with chronic phase CML and hydroxyurea-and/or interferon ␣-therapy, 13 of 15 (87%) patients with BCR-ABL positive CML in blast crisis, and 10 of 18 (56%) patients with CLL (Table 1) . In contrast, only two of nine (22%) peripheral blood samples from patients with ET and two of 10 (20%) samples from patients with ALL contained detectable cyclin A1 mRNA.
From the patients with lymphoblastic differentiation of CML blast crisis, three out of four were cyclin A1 RT-PCR positive. Whereas the patient with monoblastic differentiated CML blast crisis was cyclin A1 RT-PCR negative, all patients with myeloblastic or megakaryoblastic differentiated blast crises gave cyclin A1 RT-PCR positive results. The two cyclin A1 RT-PCR positive ALL peripheral blood samples were obtained from the two common-ALL patients at second and third relapse. Morphologically, these relapses were judged to be undifferentiated. In addition, both relapses were CD34 + . One had lost CD10 expression. No correlation between cyclin A1 expression and the presence of the Philadelphia translocation in the ALL samples was found.
Of the 162 patients, one individual with BPL was RT-PCR positive for cyclin A1 at diagnosis but became RT-PCR negative after induction of complete remission by chemotherapy. Four CML patients achieved complete cytogenetic remission after treatment with interferon ␣ and/or hydroxyurea but subsequently relapsed. Three of four were cyclin A1 RT-PCR negative during remission but all four were cyclin A1 RT-PCR positive at relapse. In contrast, one CML patient who did not respond to interferon ␣-therapy was persistently RT-PCR positive for cyclin A1.
The cyclin A1 RT-PCR product is 197 bp in size (Figure 1a ). Amplification of genomic DNA yielded two bands of approximately 900 bp and 1300 bp; a 197 bp fragment was not amplified from genomic DNA. Southern blot analysis with a specific probe for cyclin A1 demonstrated hybridization to the 197 bp cDNA product fragment and the 1300 bp genomic DNA product (Figure 1b) . To further confirm the identity of the cDNA-specific PCR product, this band was sequenced. As expected, the sequence was identical to that of the published cyclin A1 cDNA sequence. 37 No statistical significant difference between the white blood cell count of cyclin A1 RT-PCR positive and negative peripheral blood samples was found.
Cyclin A expression in leukemic cell lines
Four of six CML blast crisis cell lines examined expressed cyclin A1 mRNA in a RT-PCR assay (BV173, KCL22, KU812, LAMA; Table 2 ). The CML blast crisis cell lines K562 (two dif- ferent sources) and KYO1 gave negative results. The ALL cell line SD-1 as well as the AML cell lines HL60, KG-1a, and NB4 were cyclin A1 RT-PCR positive.
Cyclin A1 expression in individuals without hematological malignancies Using single step RT-PCR, cyclin A1 could not be detected in peripheral blood samples from seven healthy individuals. In addition, six LP were examined for cyclin A1 expression (Table 3) . Whereas the LP harvested from a patient with stage I breast cancer was cyclin A1 RT-PCR negative, one out of five LP collected from healthy individuals gave a positive result. With respect to the CD34 + cell count in the LP, the cyclin A1 RT-PCR positive LP had the highest CD34 + cell count among the LP harvested from healthy individuals.
Discussion
In this study, we examined the expression of cyclin A1 in normal and malignant hematopoietic cells. First, we have shown for the first time that cyclin A1 mRNA is expressed in the majority of myeloid and undifferentiated hematological malignancies. While cyclin A1 was expressed in all samples of patients with AML, BPL and MDS as well as in the majority of samples from patients with CML, both at diagnosis and in blastic transformation examined, only two of 10 samples from patients with ALL were cyclin A1 RT-PCR positive. Moreover, both cyclin A1 RT-PCR positive ALL were undifferentiated relapses. Furthermore, we were able to demonstrate that treatment of chronic phase CML with hydroxyurea and/or interferon ␣ leads to a 50% reduction of the rate of cyclin A1 RT-PCR positivity. The induction of a complete cytogenetic remission of CML yielded in cyclin A1 RT-PCR negativity in three of four patients.
Southern blotting of RT-PCR amplification products with a 32 P end-labeled probe internal to the cyclin A1 sequence corroborated our results. All PCR-positive lanes hybridized to this probe, whereas none of the PCR-negative lanes yielded a positive hybridization signal. DNA sequencing of the cyclin A1 RT-PCR amplification product from one peripheral blood sample of a CML patient at diagnosis yielded a sequence identical to the one originally reported. 37 Second, we confirmed the absence of cyclin A1 mRNA from mature peripheral blood leukocytes of normal individuals. However, since we found cyclin A1 mRNA expression in a LP with a high CD34
+ cell count from a healthy donor, cyclin A1 seems to be expressed in at least a subset of normal hematopoietic progenitor cells.
Third, we confirmed the expression of cyclin A1 mRNA in 37 In addition, we found cyclin A1 mRNA expression in the CML blast crisis cell lines BV173 and LAMA as well as in the lymphoblastic cell line SD-1, whereas the CML blast crisis cell lines KYO1 and K562 gave negative results. Since Yang et al. 37 reported cyclin A1 mRNA expression in K562 cells detected with the same method, we repeated the cyclin A1 RT-PCR with K562 cells from a different source, the result being negative again.
All of the genes involved in Rb regulation have been shown to be frequently altered in malignant disorders. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In contrast, alterations of cyclin A are rare. 36 Instead, in tumors expression of cyclin A in late G 1 phase seems to be a consequence of upstream alterations of the Rb/cyclin D/p16 pathway which results in release of the transcription factors E2F and CBP/cycA from Rb binding and subsequent transcriptional activation of the cyclin A gene. Although the function of cyclin A1 is still unclear, its expression in embryonic cells in Xenopus 39 and in germ line cells in mice and humans 37, 38 as well as the association with CDK2 may point to a G 1 /S phase regulatory role in germ line cells and early embryos. This contention is supported by the finding that disruption of the murine cyclin A gene leads to delayed early embryonic lethality around day 5.5 p.c. which might be explained by complementation of cyclin A function by cyclin A1 during early embryonic development. 49 Since cyclin A1 mRNA is absent from mature peripheral blood leukocytes but expressed in a LP with a high CD34
+ cell count from a healthy donor, we suggest that cyclin A1 might be necessary for proliferation and differentiation of early hematopoietic progenitor cells. Consequently, the leukemic counterparts of normal hematopoietic progenitors may express cyclin A1 because they are arrested at that early stage of differentiation.
Recently, the cyclin A1 promoter was cloned. 50 It contains multiple binding sites for the transcription factors c-myb, Sp1 and E2F. Preliminary results suggest that cyclin A1 transcription is driven by c-myb. 50 While v-myb, the viral counterpart of c-myb, is a potent inducer of myeloid leukemias, 51 c-myb is known to be involved in the regulation of hematopoiesis. C-myb expression is mostly restricted to the hematopoietic system and correlates with both the immaturity and the proliferative state of these cells. 52 It cooperatively regulates transcription of myeloid-specific genes and blocks terminal differentiation of myeloid cells. 53, 54 Targeted mutagenesis of the cmyb gene in mice leads to a reduced number of erythroid and myeloid progenitor cells. 55 In view of this, our finding of cyclin A1 expression in the majority of myeloid and undifferentiated hematological malignancies and even in two of nine peripheral blood samples from patients with ET might be a consequence of c-myb expression in these cells. Furthermore, expression of A-myb, another member of the myb transcription factor family that recognizes the same DNA sequence as c-myb, has been shown to be expressed in most B-ALL and in a subset of CLL but not in common-ALL or null-ALL. 56 This finding might explain the lack of cyclin A1 expression in the majority of common-ALL cases as well as cyclin A1 RT-PCR positivity of 56% of CLL cases investigated by us.
Interestingly, the rates of cyclin A1 RT-PCR positivity of CML in blastic transformation and at diagnosis were similar (87 and 86%, Table 1 ). Since cyclin A1 seems to be expressed early in hematopoiesis, continued expression of cyclin A1 might contribute to a proliferative advantage of a multipotent, BCR-ABL-transformed hematopoietic cell at an early stage of CML. The acquisition of genetic alterations during the course of the disease might confer additional growth advantage to these cells, associated with disease progression to blast crisis.
Taken together, in this work we describe expression of cyclin A1 in the majority of myeloid and undifferentiated hematological malignancies as well as in normal hematopoietic progenitor cells. Thus, expression of cyclin A1 in these malignancies might be a consequence of a differentiation arrest of the tumor cells at a stage where they normally express this protein. As an effector of c-myb, cyclin A1, a protein potentially involved in G 1 /S phase progression of immature cells, may contribute to cell proliferation of normal and malignant hematopoietic cells.
